Heirlume Inc announced that it has received CAD 1.7 million in funding from MaRs Discovery District, Investment Arm, NDT Pharmaceuticals Inc., Innovation Grade Ventures, The W Fund, Fastbreak Ventures, and other investors
April 27, 2021
Share
Heirlume Inc announced that it has received CAD 1,700,000 in its seed round of funidng on April 28, 2021. The transaction involved participation from new investors, MaRS Investment Accelerator Fund, a fund managed by MaRs Discovery District, Investment Arm, angel network Backbone Angels, Future Capital, Angels of Many, MaRS IAF, and angel investors, including Daniel Eberhard, Daniel Debow, Bertrand Cesvet, and Jaclyn Johnson, NDT Pharmaceuticals Inc. (OTCPK:NDTP), Innovation Grade Ventures, The W Fund, and Fastbreak Ventures.
NDT Pharmaceuticals, Inc. is a Canada-based company, which is focused on developing nutraceutical and pharmaceutical products utilizing intellectual property. The Company has acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's Nanoscale Particle Complex (NPC) technology. The intellectual property includes a versatile and widely applicable biotechnology asset base, including the Nanoscale Particle Complex (NPC) technology, which represents phospholipid-based nano-encapsulation delivery systems that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue branded by the Company as Cell Armor.
Heirlume Inc announced that it has received CAD 1.7 million in funding from MaRs Discovery District, Investment Arm, NDT Pharmaceuticals Inc., Innovation Grade Ventures, The W Fund, Fastbreak Ventures, and other investors